Introduction {#s1}
============

Preeclampsia (PE) is one of the leading causes of perinatal mortality and deaths of pregnant women worldwide [@pone.0069848-Lain1], [@pone.0069848-Roberts1]. PE is a pregnancy-specific disorder, diagnosed by *de novo* onset of hypertension and proteinuria in the latter half of pregnancy [@pone.0069848-Roberts1]--[@pone.0069848-Roberts2]. To date, there are few reliable predictive tests or any effective treatment available, except delivery of the baby and the placenta. Consequently, PE accounts for approximately 20% of all preterm births [@pone.0069848-Goldenberg1].

The aetiology of PE is not completely understood, but it is generally considered that disturbed interactions between the invading (fetal) trophoblasts and maternal cells causing defective trophoblast invasion are important pathophysiological events. The subsequent impaired spiral artery remodelling and reduced placental perfusion is proposed to create oxidative stress and a release of inflammatory factors into the maternal circulation, causing overt PE [@pone.0069848-Redman1]. Gene expression analyses may provide further insight in mechanisms of disease and function as preventive, predictive or therapeutic measures. As the molecular mechanisms behind impaired trophoblast invasion are preferentially reflected at the maternal-fetal interface, attempts to identify aberrant gene expression associated with preeclamptic pregnancies at this site have been made. So far, a number of genome-wide transcription analyses of decidual and placental bed tissue have been performed using a limited number of samples [@pone.0069848-Lian1]--[@pone.0069848-Winn1]. Findings in these studies have been inconsistent, probably reflecting lack of power in each individual study in combination with the complexity of the disease.

Women with PE often deliver preterm, due to medical indications or the condition itself. Transcriptional comparisons of gene expression in utero-placental tissue from women with PE and women with normal pregnancies are therefore often hampered by relatively large differences in gestational age. It has been shown that gene expression in utero-placental tissue differs dramatically over gestation [@pone.0069848-Mikheev1], [@pone.0069848-Winn2]. However, most studies aiming to identify altered utero-placental expression in PE have failed to properly assess changes in transcription levels caused by such differences in gestational age.

In this study, we have pooled data from three different genome-wide transcription studies [@pone.0069848-Loset1], [@pone.0069848-Winn1], [@pone.0069848-Winn2] of tissue from the maternal-fetal interface to assess differential gene expression associated with both PE and gestational age. This study is the first to include both variables (PE and gestational age), but also the first to combine data from different genome-wide platforms to analyse transcription profiles. In addition, with 154 samples analysed, this is so far the largest study performed to identify differences in expression patterns at the maternal-fetal interface.

Materials and Methods {#s2}
=====================

Microarray Datasets {#s2a}
-------------------

In this study, we have utilised three publicly available gene expression datasets from tissue from the maternal-fetal interface ([Table 1](#pone-0069848-t001){ref-type="table"}). The first dataset consist of analyses of basal plate biopsies from 36 second- and third trimester singleton pregnancies, including elective surgical terminations and normal, uncomplicated term pregnancies [@pone.0069848-Winn2]. None of these 36 samples were from women with pregnancies complicated by PE, fetal anomalies, hypertension, diabetes, infections or other significant maternal health issues. The dataset is available at the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)), accession no. GSE5999. The second dataset consists of 23 basal plate biopsies from women who developed severe PE (n = 12) or had preterm labour (n = 11) [@pone.0069848-Winn1]. Approximately one third of the cases with preterm labour resulted from cervical insufficiency, and 5 of the PE pregnancies were complicated by fetal growth restriction. Pregnancies complicated by fetal anomalies, premature rupture of the membranes, infections, diabetes, autoimmune diseases or pregnancies with multiple gestations were excluded. The dataset is available at Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)), accession no. GSE14722. The third dataset consists of 95 decidua basalis samples from women who developed PE (n = 37) and women with normal, uncomplicated term pregnancies (n = 58) [@pone.0069848-Loset1]. Among the 37 PE cases, 30 had severe PE or PE complicated by small for gestational age (SGA) and seven cases had mild PE not complicated by SGA. Pregnancies with multiple gestations, or fetal and placental anomalies (such as placenta accreta, placenta membranacea, placentas from fetuses with chromosomal anomalies or developmental anomalies, or macroscopic and microscopic signs of infection) were excluded. The dataset is available via ArrayExpress ([www.ebi.ac.uk/microarray-as/ae/](http://www.ebi.ac.uk/microarray-as/ae/)), accession no. E-TABM-682. The criteria to diagnose PE as well as severe PE in dataset \#2 and \#3 were similar [@pone.0069848-Pregnancy1], [@pone.0069848-Schroeder1]. All data used for this study have been retrieved from [www.ncbi.nlm.nih.gov/geo/or](http://www.ncbi.nlm.nih.gov/geo/or) [www.ebi.ac.uk/microarray-as/ae/](http://www.ebi.ac.uk/microarray-as/ae/), and no additional ethical approvals were obtained. A more comprehensive description of the tissue sampling and study population characteristics can be found in the original papers for the respective studies [@pone.0069848-Loset1], [@pone.0069848-Winn1], [@pone.0069848-Winn2].
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###### Descriptives of the three dataset used in this study.

![](pone.0069848.t001){#pone-0069848-t001-1}

  Dataset                       Number ofsamplesPreeclampsia(PE)            Number ofsamplesNon-PE (NP)            Mean gestationalage PE, weeks(min, max)   Mean gestationalage NP, weeks(min, max)              Microarray platform              Number ofprobes/probesets
  ---------------------------- ---------------------------------- ----------------------------------------------- ----------------------------------------- ----------------------------------------- ------------------------------------------- ---------------------------
  \#1 [@pone.0069848-Winn2]                                        2^nd^ trimester, n = 273^rd^ trimester, n = 9                                               19.3 (14.0, 24.0)38.6 (37.0, 40.0)           Affymetrix, HG-U133A&BGeneChip                  44,928
  \#2 [@pone.0069848-Winn1]          3^rd^ trimester,n = 12                   3^rd^ trimester, n = 11                         32.1 (24.1, 37.6)                         31.0 (24.7, 36.6)                   Affymetrix, HG-U133A&BGeneChip                  44,928
  \#3 [@pone.0069848-Loset1]         3^rd^ trimester,n = 37                   3^rd^ trimester, n = 58                         31.9 (25.0, 39.0)                         38.7 (37.0, 42.0)              Illumina, HumanWG-6 v2Expression Beadchip            48,095

Probe-mapping and Construction of Probe Pairs between Microarray Platforms {#s2b}
--------------------------------------------------------------------------

The transcription data that the three studies used in this work originate from has been produced on two different microarray platforms. Dataset \#1 and \#2 were analysed on Affymetrix HG-U133A&B GeneChips (Affymetrix, Santa Clara, CA, USA) including 44,928 probesets, and dataset \#3 was analysed on Illumina HumanWG-6 v2 Expression BeadChips (Illumina Inc., San Diego, CA, USA) including 48,095 probes. Affymetrix interrogates mRNA expression using a panel of different 25mer probes per transcript (probesets), whereas Illumina uses multiple, identical 50mer probes per transcript. Both platforms provide probe annotations, but since the sequence of the human genome is constantly updated, these annotations do not always match the latest updated sequence [@pone.0069848-Ballester1]. Having accurate knowledge of which transcripts the probes and probesets are measuring is essential to ensure accurate biological interpretation of the results in downstream analyses. Therefore, probes and probesets from the two platforms were remapped to Ensembl transcript predictions using the available Ensembl annotation for expression microarrays (Ensembl release 57). This Ensembl annotation was produced by first aligning the probe sequences to the corresponding genome sequence (Ensembl release 57), using the exonerate alignment tool [@pone.0069848-Slater1]. A default of one base pair mismatch was permitted between the probe and the genome sequence assembly. Probes that matched at 100 or more locations (e.g. suspected Alu repeats) were discarded. The remaining probes or probesets were associated with Ensembl transcript predictions. For Affymetrix probesets, it was required that \>50% of the probes matched a given transcript sequence. This mapping procedure is described in more detail at the Ensembl webpage ([www.ensembl.org/info/docs/microarray_probe_set_mapping.html](http://www.ensembl.org/info/docs/microarray_probe_set_mapping.html)). For the current study, Illumina-Affymetrix probe pairs were constructed if an Affymetrix probeset and an Illumina probe mapped to the same Ensembl transcript. This resulted in multiple probe pairs from some transcripts. E.g., if two different Affymetrix probesets (A1 and A2) and two Illumina probes (I1 and I2) mapped to the same transcript, this resulted in four possible probe pairs (A1--I1, A1--I2, A2--I1 and A2--I2).

Pre-processing of Microarray Data {#s2c}
---------------------------------

All pre-processing procedures were performed using the open source software R, available via [www.bioconductor.org](http://www.bioconductor.org). Affymetrix gene expression values from dataset \#1 and \#2 were imported into R and extracted using the Robust Multichip Average (RMA) method [@pone.0069848-Irizarry1] implemented in the *affy* R library. Illumina gene expression values from dataset \#3 were imported and extracted using the *lum*i R library. Both methods for extracting expression values included quantile normalisation. Next, transcription values were inverse normal transformed, for each dataset separately, to obtain perfect normally distributed values where the mean is set to zero and standard deviation to one, as described previously [@pone.0069848-Goring1]. Briefly, transcription values for all probes were first inverse normal transformed for each individual separately to adjust for variation between samples (e.g. RNA quantity). Second, the transcription values for all individuals within each substudy were inverse normal transformed for each probe, to adjust for variation between probes (e.g. probe specificity). This normalisation procedure produces comparable transcription values across individuals and transcripts (independent of RNA quality, tissue sampling method and platform etc.).

Statistical Analyses of Microarray Data {#s2d}
---------------------------------------

The normalised transcription values from the three datasets were pooled and analysed using the moderated *t*-test implemented in *limma* R library [@pone.0069848-Smyth1], [@pone.0069848-Smyth2], available via the bioconductor project ([www.bioconductor.org](http://www.bioconductor.org)). First, the transcription values were fitted to a linear model with PE-status and gestational age as covariables, as well as a factor with values (1, 2 or 3) to separate the three studies. This factor allows the mean expression level for each transcript to differ between studies, which is expected if the samples included in three studies differed in terms of gestational age, different rate of PE incidence and sampling methods. Second, an empirical Bayesian method [@pone.0069848-Smyth1] was applied to the fitted model object. To correct for multiple testing, a Bonferroni adjusted *P* value of 0.05/33,088 (number of Illumina-Affymetrix probe pairs) = 1.51\*10^−6^ was used as significance threshold in all analyses. To evaluate if the majority of the transcripts were regulated by gestational age or PE-status, the proportion of non-differentially expressed genes were estimated, as described previously [@pone.0069848-Langaas1]. In addition to the variables described above, we assessed the interaction between PE and gestational age by including an interaction term (PE\*gestational age) in the linear model.

Linear Model Fitting for Gestational Age {#s2e}
----------------------------------------

Gene expression levels are known to vary over gestation, but whether this relationship is linear throughout pregnancy is not known. In a previous study of gestational age-related transcriptional changes at the maternal-fetal interface [@pone.0069848-Winn2] (dataset \#1, [Table 1](#pone-0069848-t001){ref-type="table"}), gestational age was categorised as either mid-gestation or term, whereas we have assumed a linear relationship between gestational age and transcription levels. To evaluate if these two methods for estimating gestational age effects provided similar results, we first reanalysed dataset \#1 using the moderated *t*-test two times. The first time we used gestational age as a continuous variable, and the second time we dichotomised gestational age into mid-gestation and term. We then compared the log2 fold change (log2FC) values between analyses for each transcript.

Ingenuity Pathway Analyses {#s2f}
--------------------------

We used Ingenuity Pathway Analysis (IPA) v7.5 (Ingenuity Systems, Redwood City, CA, USA) to study the biological function of the genes that were differentially expressed in association with PE or gestational age. Fischer's exact test was used to investigate if any biological function were over-represented among these genes. No adjustment for multiple testing was done in the IPA analyses.

Concordance with Previous Studies {#s2g}
---------------------------------

To investigate whether our assessment of PE- and gestational age-related transcripts was similar to the individual three sub-studies included, we compared our results to those previously published [@pone.0069848-Loset1], [@pone.0069848-Winn1], [@pone.0069848-Winn2]. However, as the three sub-studies originally were analysed using different methods and settings, results were not directly comparable. We therefore reanalysed each dataset (\#1--\#3) separately using the moderated *t*-test, and compared these results to the results when the three datasets were pooled. For each transcript, the log2FCs corresponding to PE and gestational age were compared across datasets. In addition, we compared the top 100 most significant results (ranked by *P* value) for PE- and gestational age-related transcripts between the datasets.

Results {#s3}
=======

Study Group Characteristics and Microarray Datasets {#s3a}
---------------------------------------------------

Genome-wide transcription data from 154 tissue samples from the maternal-fetal interface, originating from three different datasets ([Table 1](#pone-0069848-t001){ref-type="table"}), were used in this work. A total of 105 non-preeclamptic (NP) controls with gestational age ranging between week 14 to 42 in addition to 49 PE cases with gestational age ranging from week 24 to 39 were included in the analyses ([Table 1](#pone-0069848-t001){ref-type="table"}).

Probe Remapping and Construction of Probe Pairs Between Microarray Platforms {#s3b}
----------------------------------------------------------------------------

A total of 33,088 Illumina-Affymetrix probe pairs (corresponding to 25,903 Affymetrix probesets and 17,933 Illumina probes) were identified by remapping probes from Affymetrix HG-U133A&B GeneChips and Illumina HumanWG-6 v2 BeadChips to Ensembl transcript predictions. These 33,088 probe pairs target 18,180 Ensembl transcripts representing 14,678 different HGNC (HUGO (Human Genome Organisation) Gene Nomenclature Committee) genes.

Linear Model Fitting for Gestational Age {#s3c}
----------------------------------------

The comparison of the two different methods for identifying gestational age-related transcripts (using gestational age as a quantitative variable versus dichotomising it to mid-gestation and term) showed that these two methods gave similar results ([Figure 1](#pone-0069848-g001){ref-type="fig"}, Pearson's product-moment correlation coefficient 0.94, *P*\<2.2\*10^−16^). Consequently, we conclude that gestational age can be used as a linear variable as well as being dichotomised into mid-gestation and term. Using a linear relationship allows for interpolation of the effect of gestational age throughout the total range of our data and compensates for the discrepancy in gestational age between datasets ([Figure 2](#pone-0069848-g002){ref-type="fig"}).

![A comparison of two methods for identifying gestational age-related transcripts; using gestational age as a linear variable age or dichotomising it to midgestation and term.\
The correlation coefficient between the log2 fold change (log2FC) values in the two methods (Pearson's product-moment correlation coefficient) is 0.94 (*P* value \<2.2\*10^−16^).](pone.0069848.g001){#pone-0069848-g001}

![Distribution of gestational ages in the three datasets.\
The figure shows the median, 1^st^ and 3^rd^ quantile, range of the data and outliers. The grey boxes represent the preeclamptic cases (PE) and white boxes represent normal pregnancies (NP).](pone.0069848.g002){#pone-0069848-g002}

PE- and Gestational Age-related Transcripts {#s3d}
-------------------------------------------

Of the 33,088 Illumina-Affymetrix probe pairs analysed, 29 were differentially expressed between PE and NP after correction for multiple testing ([Table 2](#pone-0069848-t002){ref-type="table"}). Together, these probe pairs represents 22 different transcripts. In contrast, as many as 174 probe pairs, representing 92 different transcripts, were significantly associated with gestational age ([Table 3](#pone-0069848-t003){ref-type="table"}). For the most significant observations, there were clear changes in transcription levels associated with either PE or gestational age ([Figure 3](#pone-0069848-g003){ref-type="fig"}, [Figure S1](#pone.0069848.s001){ref-type="supplementary-material"} and [S2](#pone.0069848.s002){ref-type="supplementary-material"}). We did not detect any significant interactions between PE and gestational age. Two transcripts were associated with both PE-status and gestational age; fibroblast activation protein (*FAP*) and corticotropin releasing hormone (*CRH*). *FAP* was down-regulated in PE and decreased expression over gestation, whereas *CRH* was up-regulated in PE and increased expression over gestation. The estimated fraction of differentially expressed transcripts [@pone.0069848-Langaas1] was 49% for gestational age and 30% for PE. Since transcription values for the three datasets were standardised for each transcript prior to merging, all between-study-effects such as tissue source would be excluded. We did not allow for interaction between the study/tissue source and the effect of PE or gestational age on transcription values. To evaluate if the inclusion of controls with very low gestational age affected the results, we performed the same analyses excluding controls (n = 15) with gestational age \<20 weeks. The results were very similar to the original results with a correlation between the --log10 (*P* values) for PE-associated transcripts of R = 0.96, and for the gestational age-associated transcripts r = 0.88. However, removing these 15 individuals decreased the number of significantly associated transcripts from 174 to 72 for gestational age, and from 29 to 18 for PE. Still, the ranking of the *P* values for the two subanalyses were the same (as indicated by the high correlation coefficients), and the decrease in number of significant findings most likely reflects the decrease in power by decreasing the sample size. Similarly, to test if the inclusion of cases with mild PE influenced the results, we performed the same analyses by excluding the seven cases with mild PE from dataset \#3. These results are also very similar to the primary results with a correlation coefficient between the log2FC for PE-associated transcripts of R = 0.99.

![Variation in transcription values for three selected transcripts depending on gestational age.\
Transcription values (normalised) are plotted for different gestational ages (weeks). The red points represent preeclamptic (PE) pregnancies and blue points normal pregnancies (NP). The lines are the estimated regression lines for gestational age (red line for PE, blue line for NP), separated by the regression coefficient for PE-status. In Figure A, the transcription level is significantly associated with both PE-status and gestational age. In B, the transcription level is associated with gestational age only, and in C with PE-status only.](pone.0069848.g003){#pone-0069848-g003}
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###### Preeclampsia-associated transcripts (Bonferroni corrected *P*\<0.05, nominal *P*\<1.52\*10^−6^).

![](pone.0069848.t002){#pone-0069848-t002-2}

  Gene symbol                          Description                          Fold change   *P* value   Illumina probe id   Affymetrix probe id
  ------------- ---------------------------------------------------------- ------------- ----------- ------------------- ---------------------
  *AMD1*                    adenosylmethionine decarboxylase 1                 2.20        3.6E-08      ILMN_1788462         201196_s\_at
  *AMD1*                    adenosylmethionine decarboxylase 1                 2.00        1.2E-06      ILMN_1788462           201197_at
  *ANGPTL2*                        angiopoietin-like 2                         −2.34       2.4E-09      ILMN_1772612           213001_at
  *ANGPTL2*                        angiopoietin-like 2                         −2.03       7.3E-07      ILMN_1772612           213004_at
  *CALML4*                          calmodulin-like 4                          −2.00       1.2E-06      ILMN_1652389           221879_at
  *CAMSAP1L1*    calmodulin regulated spectrin-associatedprotein 1-like 1      2.11        1.6E-07      ILMN_1792660           212763_at
  *CAMSAP1L1*    calmodulin regulated spectrin-associatedprotein 1-like 1      2.01        1.1E-06      ILMN_1792660           212765_at
  *COL6A1*                      collagen, type VI, alpha 1                     −2.06       4.1E-07      ILMN_1732151         213428_s\_at
  *CRH*                      corticotropin releasing hormone                   2.02        8.5E-07      ILMN_1668035         205629_s\_at
  *EGFR*                     epidermal growth factor receptor                  2.06        3.9E-07      ILMN_1798975         201984_s\_at
  *FAP*                    fibroblast activation protein, alpha                −1.99       1.5E-06      ILMN_1741468         209955_s\_at
  *FIBIN*                   fin bud initiation factor homolog                  −2.17       6.0E-08      ILMN_1716247           226769_at
  *KIAA1919*                             KIAA1919                              2.00        1.2E-06      ILMN_1691916         232139_s\_at
  *KIAA1919*                             KIAA1919                              2.09        2.4E-07      ILMN_1691916           238828_at
  *LIMCH1*                 LIM and calponin homology domains 1                 2.07        3.6E-07      ILMN_1664138           212325_at
  *LIMCH1*                 LIM and calponin homology domains 1                 2.18        5.0E-08      ILMN_1664138           212327_at
  *LIMCH1*                 LIM and calponin homology domains 1                 2.20        3.3E-08      ILMN_1664138           212328_at
  *MAF*           v-maf musculoaponeurotic fibrosarcomaoncogene homolog        −2.05       4.5E-07      ILMN_1719543           206363_at
  *NDFIP2*                  Nedd4 family interacting protein 2                 2.09        2.5E-07      ILMN_1677396           224799_at
  *NDFIP2*                  Nedd4 family interacting protein 2                 1.99        1.4E-06      ILMN_1677396           224801_at
  *NEBL*                                nebulette                              2.01        1.1E-06      ILMN_1808824         207279_s\_at
  *PLAC9*                          placenta-specific 9                         −1.99       1.4E-06      ILMN_1790859         227419_x\_at
  *PMP22*                      peripheral myelin protein 22                    −2.00       1.3E-06      ILMN_1785646         210139_s\_at
  *RARRES2*                 retinoic acid receptor responder 2                 −2.12       1.3E-07      ILMN_1811873           209496_at
  *SCRN1*                               secernin 1                             −2.04       5.2E-07      ILMN_1756439           201462_at
  *SERPINF1*          serpin peptidase inhibitor, clade F, member 1            −2.07       3.3E-07      ILMN_1685078           202283_at
  *SLC39A8*                 solute carrier family 39, member 8                 2.04        6.1E-07      ILMN_1695316         219869_s\_at
  *SRPX*                sushi-repeat-containing protein, X-linked              −2.18       4.5E-08      ILMN_1709486           204955_at
  *TP53INP2*          tumor protein p53 inducible nuclear protein 2            −2.10       2.0E-07      ILMN_1686906           224836_at

10.1371/journal.pone.0069848.t003

###### Gestational age-associated transcripts (Bonferroni corrected *P*\<0.05, nominal *P*\<1.52^\*^10^−6^).

![](pone.0069848.t003){#pone-0069848-t003-3}

  Gene symbol                                              Description                                            Fold change(per week)   *P* value   Illumina probe id   Affymetrix probe id
  -------------- ----------------------------------------------------------------------------------------------- ----------------------- ----------- ------------------- ---------------------
  *ADAMTS5*                         ADAM metallopeptidase with thrombospondintype 1 motif, 5                             −1.057            3.6E-07      ILMN_1671747           219935_at
  *ADAMTS5*                         ADAM metallopeptidase with thrombospondintype 1 motif, 5                             −1.057            3.7E-07      ILMN_1671747           229357_at
  *ADAMTS5*                         ADAM metallopeptidase with thrombospondintype 1 motif, 5                             −1.055            9.0E-07      ILMN_1671747           235368_at
  *ANGPT2*                                               angiopoietin 2                                                  −1.059            2.0E-07      ILMN_1774207           205572_at
  *ANGPT2*                                               angiopoietin 2                                                  −1.056            7.6E-07      ILMN_1774207         211148_s\_at
  *ANGPT2*                                               angiopoietin 2                                                  −1.058            2.6E-07      ILMN_1774207           236034_at
  *ANGPT2*                                               angiopoietin 2                                                  −1.058            2.3E-07      ILMN_1774207           237261_at
  *ANKRD50*                                         ankyrin repeat domain 50                                             −1.055            9.6E-07      ILMN_1729342           225731_at
  *ANKRD50*                                         ankyrin repeat domain 50                                             −1.057            5.1E-07      ILMN_1729342           225735_at
  *APH1B*                              anterior pharynx defective 1 homolog B (C. elegans)                               −1.055            9.3E-07      ILMN_1862217           226358_at
  *ASPH*                                           aspartate beta-hydroxylase                                            -−1.055           1.0E-06      ILMN_1693771           224996_at
  *ASPH*                                           aspartate beta-hydroxylase                                            −1.055            1.0E-06      ILMN_1739719           224996_at
  *ASS1*                                          argininosuccinate synthase 1                                           −1.058            2.9E-07      ILMN_1688234         207076_s\_at
  *ATP1B1*                               ATPase, Na+/K+ transporting, beta 1 polypeptide                                 −1.055            9.2E-07      ILMN_1736862         201243_s\_at
  *ATP2B4*                                ATPase, Ca++ transporting, plasma membrane 4                                   −1.055            1.0E-06      ILMN_1664772           212136_at
  *ATP6V1E1*                         ATPase, H+ transporting, lysosomal 31kDa, V1subunit E1                               1.055            1.1E-06      ILMN_1798485           208678_at
  *BCAT1*                              branched chain amino-acid transaminase 1, cytosolic                               −1.055            1.2E-06      ILMN_1766169           225285_at
  *BCAT1*                              branched chain amino-acid transaminase 1, cytosolic                               −1.057            5.1E-07      ILMN_1766169           226517_at
  *BMP6*                                          bone morphogenetic protein 6                                            1.064            1.7E-08      ILMN_1747650           206176_at
  *C1orf115*                                   chromosome 1 open reading frame 115                                        1.055            1.1E-06      ILMN_1674817           218546_at
  *C20orf194*                                 chromosome 20 open reading frame 194                                       −1.056            7.1E-07      ILMN_1673005           225825_at
  *C3orf58*                                    chromosome 3 open reading frame 58                                        −1.056            8.0E-07      ILMN_1797372           226464_at
  *CAB39L*                                       calcium binding protein 39-like                                         −1.058            2.8E-07      ILMN_1730529         225914_s\_at
  *CAB39L*                                       calcium binding protein 39-like                                         −1.057            5.3E-07      ILMN_1660815         225914_s\_at
  *CAB39L*                                       calcium binding protein 39-like                                          1.060            1.3E-07      ILMN_1665449           226028_at
  *CAPN6*                                                   calpain 6                                                     1.057            3.5E-07      ILMN_1782654         202965_s\_at
  *CCNYL1*                                               cyclin Y-like 1                                                 −1.055            1.1E-06      ILMN_1810069         227280_s\_at
  *CD200*                                                CD200 molecule                                                   1.065            1.2E-08      ILMN_1706722         209582_s\_at
  *CD200*                                                CD200 molecule                                                   1.063            3.0E-08      ILMN_1706722         209583_s\_at
  *CDH11*                                 cadherin 11, type 2, OB-cadherin (osteoblast)                                  −1.059            1.5E-07      ILMN_1672611         207172_s\_at
  *CDH11*                                 cadherin 11, type 2, OB-cadherin (osteoblast)                                  −1.066            6.5E-09      ILMN_1672611         207173_x\_at
  *CEACAM1*              carcinoembryonic antigen-related cell adhesionmolecule 1 (biliary glycoprotein)                  1.059            1.5E-07      ILMN_1716815           209498_at
  *CEACAM1*              carcinoembryonic antigen-related cell adhesionmolecule 1 (biliary glycoprotein)                  1.057            4.2E-07      ILMN_1664330           209498_at
  *CEBPB*                                 CCAAT/enhancer binding protein (C/EBP), beta                                    1.056            8.0E-07      ILMN_1693014           212501_at
  *CETP*                                   cholesteryl ester transfer protein, plasma                                     1.059            1.8E-07      ILMN_1681882         206210_s\_at
  *CITED2*              Cbp/p300-interacting transactivator, withGlu/Asp-rich carboxy-terminal domain, 2                 −1.060            1.2E-07      ILMN_1663092           209357_at
  *CMPK1*                              cytidine monophosphate (UMP-CMP) kinase 1,cytosolic                               −1.057            3.9E-07      ILMN_1738642         217870_s\_at
  *COL14A1*                                        collagen, type XIV, alpha 1                                           −1.055            9.5E-07      ILMN_1786598         212865_s\_at
  *COL1A2*                                          collagen, type I, alpha 2                                            −1.057            3.6E-07      ILMN_1785272         202403_s\_at
  *COL1A2*                                         collagen, type XXI, alpha 1                                           −1.060            1.1E-07      ILMN_1785272         202404_s\_at
  *COL21A1*                                        collagen, type III, alpha 1                                           −1.063            3.3E-08      ILMN_1732850         208096_s\_at
  *COL3A1*                                         collagen, type III, alpha 1                                           −1.060            1.3E-07      ILMN_1773079         201852_x\_at
  *COL3A1*                                         collagen, type III, alpha 1                                           −1.058            2.3E-07      ILMN_1773079         211161_s\_at
  *COL3A1*                                         collagen, type III, alpha 1                                           −1.058            3.4E-07      ILMN_1773079         215076_s\_at
  *COL5A1*                                          collagen, type V, alpha 1                                            −1.056            6.7E-07      ILMN_1706505           212489_at
  *COL5A2*                                          collagen, type V, alpha 2                                            −1.059            1.9E-07      ILMN_1729117           221729_at
  *COL5A2*                                          collagen, type V, alpha 2                                            −1.055            9.7E-07      ILMN_1729117           221730_at
  *COL6A3*                                         collagen, type VI, alpha 3                                            −1.065            1.2E-08      ILMN_1706643           201438_at
  *CRH*                                          corticotropin releasing hormone                                          1.059            2.0E-07      ILMN_1668035         205629_s\_at
  *CTSC*                                                   cathepsin C                                                   −1.059            2.2E-07      ILMN_1792885           225646_at
  *CTSC*                                                   cathepsin C                                                   −1.056            6.3E-07      ILMN_1689086           225646_at
  *CUX1*                                               cut-like homeobox 1                                               −1.055            1.2E-06      ILMN_1727603           225221_at
  *DCN*                                                      decorin                                                     −1.059            1.7E-07      ILMN_1701748           209335_at
  *DCN*                                                      decorin                                                     −1.058            2.9E-07      ILMN_1768227           209335_at
  *DCN*                                                      decorin                                                     −1.057            5.1E-07      ILMN_1666672           209335_at
  *DCN*                                                      decorin                                                     −1.055            9.4E-07      ILMN_1701748         211896_s\_at
  *DEPDC7*                                           DEP domain containing 7                                             −1.057            4.5E-07      ILMN_1718152           228293_at
  *DUSP1*                                        dual specificity phosphatase 1                                           1.060            9.7E-08      ILMN_1781285         201041_s\_at
  *EFHD1*                                       EF-hand domain family, member D1                                          1.055            1.2E-06      ILMN_1779448           209343_at
  *EHBP1*                                          EH domain binding protein 1                                           −1.056            6.3E-07      ILMN_1803348         212653_s\_at
  *ELOVL6*        ELOVL family member 6, elongation of long chainfatty acids (FEN1/Elo2, SUR4/Elo3-like, yeast)          −1.058            2.5E-07      ILMN_1700546           204256_at
  *ERG*                             v-ets erythroblastosis virus E26 oncogenehomolog (avian)                              1.054            1.3E-06      ILMN_1768301         213541_s\_at
  *FABP4*                                    fatty acid binding protein 4, adipocyte                                      1.074            7.1E-11      ILMN_1773006           203980_at
  *FADS1*                                            fatty acid desaturase 1                                             −1.058            2.5E-07      ILMN_1670134         208962_s\_at
  *FAP*                                       fibroblast activation protein, alpha                                       −1.055            1.1E-06      ILMN_1741468         209955_s\_at
  *FBXO42*                                              F-box protein 42                                                  1.057            4.3E-07      ILMN_1756874           221813_at
  *FKBP14*                                      FK506 binding protein 14, 22 kDa                                         −1.056            8.6E-07      ILMN_1665243           230728_at
  *FKBP7*                                            FK506 binding protein 7                                             −1.057            4.2E-07      ILMN_1717737         224002_s\_at
  *FNBP1L*                                        formin binding protein 1-like                                          −1.058            3.3E-07      ILMN_1754600         215017_s\_at
  *GALNT3*        UDP-N-acetyl-alpha-D-galactosamine:polypeptideN-acetylgalactosaminyltransferase 3 (GalNAc-T3)          −1.056            8.3E-07      ILMN_1671039         203397_s\_at
  *GAS1*                                            growth arrest-specific 1                                             −1.056            6.6E-07      ILMN_1772910         204457_s\_at
  *GFOD2*                              glucose-fructose oxidoreductase domaincontaining 2                                 1.055            1.1E-06      ILMN_1744006         221028_s\_at
  *GJA1*                                      gap junction protein, alpha 1, 43kDa                                       −1.062            5.3E-08      ILMN_1727087           201667_at
  *GLB1*                                              galactosidase, beta 1                                              −1.058            2.5E-07      ILMN_1790862         201576_s\_at
  *GLUL*                                            glutamate-ammonia ligase                                             −1.061            8.8E-08      ILMN_1678881         215001_s\_at
  *GLUL*                                            glutamate-ammonia ligase                                             −1.056            6.3E-07      ILMN_1653496         215001_s\_at
  *GPSM1*                                        G-protein signaling modulator 1                                         −1.060            9.5E-08      ILMN_1751666           226043_at
  *GPSM1*                                        G-protein signaling modulator 1                                         −1.056            6.3E-07      ILMN_1709307           226043_at
  *GPSM1*                                        G-protein signaling modulator 1                                         −1.056            7.1E-07      ILMN_1796392           226043_at
  *GPX8*                                       glutathione peroxidase 8 (putative)                                       −1.058            2.3E-07      ILMN_1767665           228141_at
  *HAPLN1*                                 hyaluronan and proteoglycan link protein 1                                    −1.056            6.7E-07      ILMN_1678812         205524_s\_at
  *HBD*                                                 hemoglobin, delta                                                 1.061            5.5E-08      ILMN_1815527           206834_at
  *HOMER1*                                        homer homolog 1 (Drosophila)                                           −1.056            7.2E-07      ILMN_1804568         213793_s\_at
  *HOMER1*                                        homer homolog 1 (Drosophila)                                           −1.057            4.5E-07      ILMN_1804568           226651_at
  *IDH1*                                   isocitrate dehydrogenase 1 (NADP+), soluble                                   −1.061            6.0E-08      ILMN_1696432           201193_at
  *IL6ST*                                        interleukin 6 signal transducer                                         −1.065            9.6E-09      ILMN_1849013           212195_at
  *IL6ST*                                        interleukin 6 signal transducer                                         −1.061            5.8E-08      ILMN_1797861           212195_at
  *IL6ST*                                        interleukin 6 signal transducer                                         −1.059            1.6E-07      ILMN_1746604           212195_at
  *ITGA1*                                               integrin, alpha 1                                                −1.055            9.8E-07      ILMN_1802411           214660_at
  *KCTD12*                            potassium channel tetramerisationdomain containing 12                              −1.057            4.7E-07      ILMN_1742332           212192_at
  *KDELR3*                  KDEL (Lys-Asp-Glu-Leu) endoplasmicreticulum protein retention receptor 3                     −1.056            6.0E-07      ILMN_1713901           204017_at
  *KIAA1598*                                                KIAA1598                                                     −1.055            1.3E-06      ILMN_1805992         221802_s\_at
  *KLF2*                                          Kruppel-like factor 2 (lung)                                           −1.060            1.2E-07      ILMN_1735930         219371_s\_at
  *KREMEN1*                                kringle containing transmembrane protein 1                                     1.059            2.1E-07      ILMN_1772697           227250_at
  *LDLR*                                        low density lipoprotein receptor                                         −1.056            8.1E-07      ILMN_1651611         202068_s\_at
  *LGALS3*                                   lectin, galactoside-binding, soluble, 3                                     −1.055            1.2E-06      ILMN_1665479         208949_s\_at
  *LGALS3*                                   lectin, galactoside-binding, soluble, 3                                     −1.061            6.1E-08      ILMN_1747118         208949_s\_at
  *LGALS8*                                   lectin, galactoside-binding, soluble, 8                                     −1.059            1.8E-07      ILMN_1669930         208934_s\_at
  *LGALS8*                                   lectin, galactoside-binding, soluble, 8                                      1.059            2.1E-07      ILMN_1669930         208936_x\_at
  *LIMA1*                                        LIM domain and actin binding 1                                           1.056            6.7E-07      ILMN_1704369         217892_s\_at
  *LMO4*                                                LIM domain only 4                                                −1.055            9.4E-07      ILMN_1703487           227155_at
  *LUM*                                                      lumican                                                     −1.056            7.7E-07      ILMN_1790529         201744_s\_at
  *MAN1A1*                                   mannosidase, alpha, class 1A, member 1                                      −1.056            6.8E-07      ILMN_1742187           221760_at
  *MCC*                                           mutated in colorectal cancers                                          −1.063            3.0E-08      ILMN_1795503           226225_at
  *MFSD2A*                              major facilitator superfamily domaincontaining 2A                                −1.054            1.5E-06      ILMN_1798284           225316_at
  *MMRN2*                                                 multimerin 2                                                    1.055            1.0E-06      ILMN_1715788         219091_s\_at
  *NAP1L1*                                    nucleosome assembly protein 1-like 1                                        1.057            4.5E-07      ILMN_1705876         208752_x\_at
  *NAP1L1*                                    nucleosome assembly protein 1-like 1                                       −1.056            6.5E-07      ILMN_1705876         208753_s\_at
  *NAP1L1*                                    nucleosome assembly protein 1-like 1                                       −1.059            2.2E-07      ILMN_1699208         208753_s\_at
  *NAP1L1*                                    nucleosome assembly protein 1-like 1                                       −1.056            7.7E-07      ILMN_1705876         213864_s\_at
  *NAP1L1*                                    nucleosome assembly protein 1-like 1                                       −1.064            1.9E-08      ILMN_1699208         213864_s\_at
  *NDRG2*                                             NDRG family member 2                                               −1.061            7.4E-08      ILMN_1670535         206453_s\_at
  *NID1*                                                    nidogen 1                                                     1.055            9.5E-07      ILMN_1674719           202007_at
  *NID2*                                            nidogen 2 (osteonidogen)                                             −1.060            1.4E-07      ILMN_1698706           204114_at
  *NPL*                         N-acetylneuraminate pyruvate lyase(dihydrodipicolinate synthase)                         −1.062            5.3E-08      ILMN_1782070         221210_s\_at
  *OAT*                                            ornithine aminotransferase                                            −1.056            7.8E-07      ILMN_1654441           201599_at
  *OLA1*                                                Obg-like ATPase 1                                                −1.058            2.4E-07      ILMN_1659820         219293_s\_at
  *OLFML3*                                             olfactomedin-like 3                                               −1.057            4.9E-07      ILMN_1727532           218162_at
  *PAPLN*                                papilin, proteoglycan-like sulfatedglycoprotein                                 −1.060            9.7E-08      ILMN_1710495           226435_at
  *PCYOX1*                                          prenylcysteine oxidase 1                                             −1.061            8.3E-08      ILMN_1679725           225274_at
  *PDGFRA*                          platelet-derived growth factor receptor,alpha polypeptide                            −1.055            1.2E-06      ILMN_1681949           203131_at
  *PDZRN3*                                     PDZ domain containing ring finger 3                                       −1.056            8.5E-07      ILMN_1699552           212915_at
  *PDZRN3*                                     PDZ domain containing ring finger 3                                       −1.055            1.2E-06      ILMN_1703511           212915_at
  *PLA2G7*              phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)                 −1.061            7.4E-08      ILMN_1701195           206214_at
  *PPL*                                                    periplakin                                                     1.058            2.4E-07      ILMN_1806030           203407_at
  *PPP1R14C*                        protein phosphatase 1, regulatory(inhibitor) subunit 14C                              1.056            8.4E-07      ILMN_1664855           226907_at
  *PTPRB*                                       RAB6B, member RAS oncogene family                                         1.055            1.0E-06      ILMN_1821052           205846_at
  *RAB6B*                           roundabout, axon guidance receptor,homolog 1 (Drosophila)                             1.059            1.4E-07      ILMN_1752299           225259_at
  *ROBO1*                                         ribosomal protein, large, P0                                           −1.060            1.1E-07      ILMN_1806790           213194_at
  *RPLP0*                                         ribosomal protein, large, P0                                           −1.059            1.5E-07      ILMN_1709880         201033_x\_at
  *RPLP0*                                         ribosomal protein, large, P0                                           −1.057            5.3E-07      ILMN_1748471         201033_x\_at
  *RPLP0*                                         ribosomal protein, large, P0                                           −1.055            9.9E-07      ILMN_1709880         208856_x\_at
  *RPLP0*                                         ribosomal protein, large, P0                                           −1.057            4.2E-07      ILMN_1709880         211720_x\_at
  *RPLP0*                                         ribosomal protein, large, P0                                           −1.055            1.2E-06      ILMN_1709880         211972_x\_at
  *RPS2*                                       ribosomal protein S2, pseudogene 6                                        −1.061            6.4E-08      ILMN_1662982         203107_x\_at
  *RPS2*                                       ribosomal protein S2, pseudogene 6                                        −1.063            2.9E-08      ILMN_1662982         212433_x\_at
  *RPS2*                                       ribosomal protein S2, pseudogene 6                                        −1.061            8.7E-08      ILMN_1709604         212433_x\_at
  *SC4MOL*                                        sterol-C4-methyl oxidase-like                                          −1.058            3.0E-07      ILMN_1720889           209146_at
  *SC4MOL*                                        sterol-C4-methyl oxidase-like                                          −1.057            4.8E-07      ILMN_1689842           209146_at
  *SESTD1*                                        SEC14 and spectrin domains 1                                           −1.059            2.0E-07      ILMN_1782341           226763_at
  *SLC2A10*                    solute carrier family 2 (facilitatedglucose transporter), member 10                       −1.062            4.2E-08      ILMN_1663351         221024_s\_at
  *SLC39A10*                          solute carrier family 39 (zinctransporter), member 10                              −1.055            1.1E-06      ILMN_1656129           225295_at
  *SMYD3*                                       SET and MYND domain containing 3                                         −1.056            7.8E-07      ILMN_1741954         218788_s\_at
  *SNORA10*                                     small nucleolar RNA, H/ACA box 10                                        −1.059            1.9E-07      ILMN_1709604         203107_x\_at
  *SOAT1*                                          sterol O-acyltransferase 1                                            −1.062            4.8E-08      ILMN_1699100           221561_at
  *SOAT1*                                          sterol O-acyltransferase 1                                            −1.062            4.1E-08      ILMN_1699100           228479_at
  *SPP1*                                            secreted phosphoprotein 1                                            −1.059            2.0E-07      ILMN_1651354         209875_s\_at
  *STAT5B*                             signal transducer and activator oftranscription 5B                                 1.055            1.2E-06      ILMN_1777783           205026_at
  *STX3*                                                   syntaxin 3                                                     1.056            5.9E-07      ILMN_1659544           209238_at
  *SVIL*                                                   supervillin                                                   −1.054            1.3E-06      ILMN_1671404         202565_s\_at
  *SYNPO*                                                 synaptopodin                                                    1.057            3.6E-07      ILMN_1711491           202796_at
  *TCF7L2*                           transcription factor 7-like 2(T-cell specific, HMG-box)                             −1.055            1.1E-06      ILMN_1672486         212759_s\_at
  *TCF7L2*                           transcription factor 7-like 2(T-cell specific, HMG-box)                             −1.059            1.7E-07      ILMN_1672486           212761_at
  *TCF7L2*                           transcription factor 7-like 2(T-cell specific, HMG-box)                             −1.058            2.6E-07      ILMN_1672486         212762_s\_at
  *TCF7L2*                           transcription factor 7-like 2(T-cell specific, HMG-box)                             −1.063            2.3E-08      ILMN_1672486         216035_x\_at
  *TCF7L2*                           transcription factor 7-like 2(T-cell specific, HMG-box)                             −1.060            1.4E-07      ILMN_1672486         216037_x\_at
  *TMEM150C*                                       transmembrane protein 150C                                            −1.056            8.3E-07      ILMN_1797047           229623_at
  *TPPP3*                            tubulin polymerization-promoting proteinfamily member 3                              1.057            3.9E-07      ILMN_1797744           218876_at
  *TTC3L*                                       tetratricopeptide repeat domain 3                                        −1.055            9.7E-07      ILMN_1761476         210645_s\_at
  *TUBB*                                                  tubulin, beta                                                  −1.056            6.1E-07      ILMN_1665583           212320_at
  *TUBB*                                                  tubulin, beta                                                  −1.054            1.4E-06      ILMN_1703692           212320_at
  *unspecific*                                                                                                           −1.060            1.1E-07      ILMN_1748471         211720_x\_at
  *unspecific*                                                                                                           −1.058            3.5E-07      ILMN_1748471         211972_x\_at
  *UQCRH*                              ubiquinol-cytochrome c reductase hingeprotein-like                                −1.055            1.1E-06      ILMN_1718136         202233_s\_at
  *VCAN*                                                    versican                                                     −1.057            3.6E-07      ILMN_1687301         204619_s\_at
  *VCAN*                                                    versican                                                     −1.058            2.4E-07      ILMN_1687301         204620_s\_at
  *VCAN*                                                    versican                                                     −1.058            2.5E-07      ILMN_1687301         211571_s\_at
  *VCAN*                                                    versican                                                     −1.058            2.3E-07      ILMN_1687301         215646_s\_at
  *WARS*                                          tryptophanyl-tRNA synthetase                                            1.055            1.1E-06      ILMN_1727271           200629_at
  *WNT5A*                             wingless-type MMTV integration site family,member 5A                               −1.054            1.4E-06      ILMN_1800317           213425_at
  *XPOT*                                                 exportin, tRNA                                                  −1.055            1.3E-06      ILMN_1743711           212160_at
  *ZFHX3*                                            zinc finger homeobox 3                                              −1.060            1.2E-07      ILMN_1808587           226137_at
  *ZFP42*                                    zinc finger protein 42 homolog (mouse)                                      −1.054            1.4E-06      ILMN_1751127         243161_x\_at
  *ZKSCAN1*                                 zinc finger with KRAB and SCAN domains 1                                     −1.055            1.0E-06      ILMN_1687567           225935_at

Ingenuity Pathway Analyses {#s3e}
--------------------------

IPA analysis of the 22 PE-associated transcripts ([Table 2](#pone-0069848-t002){ref-type="table"}) identified in our analyses demonstrated an over-representation of biological functions such as cellular growth and proliferation, cell death, endocrine system disorders and metabolic disease ([Table 4](#pone-0069848-t004){ref-type="table"}). IPA analysis of the 92 gestational age-associated transcripts ([Table 3](#pone-0069848-t003){ref-type="table"}) demonstrated over-representation of the biological functions cellular assembly and organisation, tissue development, cellular movement, cardiovascular system development and function, cellular growth and proliferation, connective tissue development, cell-to-cell signalling and interaction, and cell cycle ([Table 5](#pone-0069848-t005){ref-type="table"}).

10.1371/journal.pone.0069848.t004

###### Ingenuity Pathway Analysis of preeclampsia-associated transcripts.

![](pone.0069848.t004){#pone-0069848-t004-4}

  Biological functions                                             Genes included                                       *P* value
  ----------------------------------- ------------------------------------------------------------------------ ---------------------------
  Cellular growth and proliferation                     *COL6A1, CRH, EGFR, PMP22, SERPINF1*                    2.92\*10^−4^−4.40\*10^−2^
  Cell death                                             *CRH, EGFR, FAP, PMP22, SERPINF1*                      1.28\*10^−3^−1.53\*10^−2^
  Endocrine system disorders           *CAMSAP1L1, CRH, EGFR, KIAA1919, LIMCH1, NEBL, PMP22, SCRN1, SERPINF1*   2.57\*10^−3^−2.86\*10^−2^
  Metabolic disease                       *CAMSAP1L1, CRH, KIAA1919, LIMCH1, NEBL, PMP22, SCRN1, SERPINF1*      2.30\*10^−3^−2.57\*10^−2^

10.1371/journal.pone.0069848.t005

###### Ingenuity Pathway Analysis of gestational age-associated transcripts.

![](pone.0069848.t005){#pone-0069848-t005-5}

  Biological functions                                                                                                                                    Genes included                                                                                                                  *P* value
  ----------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------
  Cellular assembly and organization                                                                                            *COL1A2, COL3A1, COL5A1, COL5A2, LIMA1, VCAN, IL6ST, NID1, LGALS3*                                                                                1.88\*10^−7^−1.12\*10^−2^
  Tissue development                                                                   *BMP6, CDH11, CITED2, COL1A2, COL3A1, COL5A1, COL5A2, COL6A3, DCN, ERG,* *IL6ST, ITGA1, KLF2, LGALS3, LGALS8, NID1, SVIL, TCF7L2, VCAN, WNT5A, SPP1*                                       3.31\*10^−5^−1.05\*10^−2^
  Cellular movement                                                                                      *BMP6, CDH11, CEACAM1, CITED2, DCN, FAP, GJA1, ITGA1, LGALS3, PDGFRA,* *ROBO1, SPP1, TCF7L2, VCAN, WARS, WNT5A*                                                          5.35\*10^−5^−1.02\*10^−2^
  Cardiovascular system developmentand function                                                                              *BMP6, CEACAM1, CITED2, COL1A2, COL3A1, DCN, ITGA1, TCF7L2, WARS, WNT5A*                                                                             2.82\*10^−4^−2.19\*10^−2^
  Cellular growth and proliferation                *BCAT1, BMP6, CDH11, CEACAM1, CEBPB, CITED2, COL6A3, COL14A1, CRH, CTSC,* *CUX1, DCN, DUSP1, ERG, FADS1, GAS1, GJA1, GLUL, IL6ST, ITGA1, KLF2, LGALS3,* *MCC, NAP1L1, PDGFRA, SOAT1, SPP1, TCF7L2, VCAN, WARS, WNT5A, ZFHX3*   4.04\*10^−4^−1.46\*10^−2^
  Connective tissue development                                                                                                     *CDH11, COL14A1, IL6ST, PDGFRA, SPP1, TCF7L2, VCAN, WNT5A*                                                                                    1.04\*10^−3^−1.46\*10^−2^
  Cell-to-cell signaling and interaction                                                                *BMP6, CD200,CEACAM1,CEBPB, CRH, DCN, ERG, IL6ST, ITGA1, LDLR, LGALS3,* *LGALS8, NID1, PDGFRA, SPP1, VCAN, WNT5A*                                                         3.96\*10^−3^−1.46\*10^−2^
  Cell cycle                                                                                                                           *BCAT1, BMP6, CEBPB, CRH, DCN, DUSP1, GJA1, LGALS3*                                                                                        7.35\*10^−3^−1.22\*10^−2^

Concordance with Previous Studies {#s3f}
---------------------------------

Since the number of significant transcripts in the previous publications of the included datasets was very limited when applying a stringent threshold for multiple testing (Bonferroni), no rigorously comparison between datasets could be performed. However, lists of transcripts/probes that were claimed to be differentially expressed in the three original studies are included ([Tables S1](#pone.0069848.s003){ref-type="supplementary-material"}--[S3](#pone.0069848.s004){ref-type="supplementary-material"}). A comparison of our reanalysis of dataset \#1 with 36 NP samples and our analyses of all three datasets combined with 154 samples showed that the log2FC values for gestational age-associated transcripts were highly correlated (Pearson's product-moment correlation coefficient 0.94, *P*\<2.2\*10^−16^). In addition, the top 100 transcripts from the reanalysis of dataset \#1 were all nominally significant (*P*\<0.05) in our analysis of the pooled datasets and 20 transcripts were shared between the top 100 transcripts from dataset \#1 and the pooled analyses.

Comparing our separate reanalyses of dataset \#2 and \#3 (with 12 or 37 PE samples and 11 or 58 NP samples, respectively) with our analysis of the pooled dataset (49 PE and 105 NP), we found that the correlation between the log2FC values for PE in dataset \#2 and the pooled dataset (Pearson's product-moment correlation coefficient 0.57, *P*\<2.2\*10^−16^) were similar to the correlation between the PE log2FC values for dataset \#3 and the pooled dataset (Pearson's product-moment correlation coefficient 0.71, *P*\<2.2\*10^−16^). For the sub-analysis of PE-associated transcripts in dataset \#2, 78 of the top 100 transcripts were nominally significant (*P*\<0.05) in our pooled analyses of PE-associated transcripts, but only two of these were significant in the pooled analyses after correction for multiple testing and four transcripts were shared between the top 100 transcripts from dataset \#2 and the pooled analyses. For the reanalysis of dataset \#3, 93 of the top 100 transcripts were nominally significant (*P*\<0.05) in our total analysis, of which nine were significant in the pooled dataset after correction for multiple testing. Seven transcripts were shared between the top 100 transcripts from dataset \#3 and the pooled analyses. The correlation between dataset \#2 and \#3 log2FC values from the PE-associated transcripts was low (Pearson's product-moment correlation coefficient 0.04, *P*\<1.04\*10^−13^). This is not surprising, since none of the PE-associated transcripts in dataset \#2 and only two in dataset \#2 were significant after correcting for multiple testing (Bonferroni).

Discussion {#s4}
==========

In this work, we have pooled data from three different genome-wide transcription analyses of samples from the maternal-fetal interface to generate a dataset consisting of 154 samples. To the best of our knowledge, this is the largest dataset used to assess changes in transcription levels associated with either PE or gestational age. A total of 92 gestational age-related and 22 PE-associated transcripts were identified. These numbers by themselves indicates that a large fraction of variance in transcription levels at the maternal-fetal interface can be attributed to gestational age rather than PE-status. The large sample size achieved by pooling datasets from three different studies enabled us to apply a stringent significance threshold (Bonferroni adjusted *P* values) in order to minimise the probability of false positives. Using Bonferroni cut-off of 0.05 corresponds to false discovery rate (FDR) cut-offs of 2.8\*10^−4^ for gestational age and 1.7\*10^−3^ for PE [@pone.0069848-Benjamini1]. Previous genome-wide transcription studies on PE have not used such stringent threshold for significance, and those findings should be interpreted with care. In accordance with this, only few PE- or gestational age- associated transcripts from previous publications have been replicated in others or our study.

The most significant finding among the PE-associated transcripts was the down-regulation (*P* = 2.43\*10^−9^, \>2 fold down-regulated) of angiopoietin-like 2 (*ANGPTL2*). The *ANGPTL2* protein is a secreted glycoprotein with homology to the angiopoietins, which are important angiogenic factors. Although the angiopoietin-like proteins do not bind to the angiopoietin receptor, they are believed to play a role in angiogenesis via induction of endothelial cell sprouting in blood vessels [@pone.0069848-Kim1]. We also observed a down-regulation of *RARRES2* (retinoic acid receptor responder 2, also called chemerin) among the PE-associated transcripts. It was recently demonstrated that chemerin could induce angiogenesis *in vitro* [@pone.0069848-Bozaoglu1], [@pone.0069848-Kaur1]. Down-regulation of these angiogenic factors may be linked to the pathogenesis of PE through abnormal vascular morphology, as placentas from women with severe PE, especially in combination with fetal growth restriction, are characterised by decreased capillary volume and surface area [@pone.0069848-Egbor1].

The expression of *CRH* and *FAP* were significantly associated with both PE-status and gestational age. While the expression of *CRH* increased with gestational age and was up-regulated in PE, the expression of *FAP* decreased with gestational age and was down-regulated in PE. The transcriptional changes of *FAP* and *CRH* are probably linked to both gestational age and PE. During pregnancy, *CRH* is produced by decidual and placental tissue [@pone.0069848-Wetzka1], and released into the fetal and maternal circulation. Maternal plasma *CRH* levels increase over gestation [@pone.0069848-McLean1], concurrent with our observation of *CRH* among the gestational age-related transcripts. A further elevation of maternal plasma *CRH* levels has been shown in PE compared to normal pregnancies at the same gestational age [@pone.0069848-Perkins1]. Increased levels of *CRH* may contribute to the pathogenesis of PE trough its role in regulation of vascular resistance and blood flow in utero-placental tissue [@pone.0069848-Clifton1].

Among the transcripts that were up- or down- regulated due to gestational age, we noted decreased expression of galectin 3 (*LGALS3*) and increased expression of galectin (*LGALS8*). Galectins are highly expressed at the maternal-fetal interface, and regarded as multifunctional regulators of fundamental cellular processes due to their capacity to modulate functions such as cell-extracellular matrix interactions, proliferation, adhesion, and invasion [@pone.0069848-Than1]. Galectin 3 is expressed in placental cell columns, but not in invasive extravillous trophoblasts [@pone.0069848-vandenBrule1]. The negative correlation between expression and trophoblast invasiveness is in accordance with our finding of decreased galectin 3 expression over gestation. Galectin 8 is expressed by decidual cells, villous and extravillous trophoblasts [@pone.0069848-Kolundzic1], but its role is less clearly understood.

The IPA analyses of the 22 PE-associated transcripts demonstrated an over-representation of genes associated with metabolic disease ([Table 4](#pone-0069848-t004){ref-type="table"}). PE share several metabolic abnormalities with cardiovascular diseases and diabetes, and having a PE complicated pregnancy is associated with increased risk of type 2 diabetes later in life [@pone.0069848-Carr1]. This agrees with pregnancy acting as a stress factor which could reveal a pre-existing disposition to later life metabolic disease [@pone.0069848-Williams1]. IPA analysis of the 92 transcripts that were associated with gestational age revealed an over-representation of genes involved in cell assembly and organisation, tissue development, cellular movement, tissue morphology, and connective tissue development and function ([Table 5](#pone-0069848-t005){ref-type="table"}). These findings are in agreement with known biological processes taking place at the maternal-fetal interface during pregnancy, such as trophoblast proliferation, differentiation, invasion and extracellular matrix remodelling.

It is important to consider that the data used in our study was produced on two different microarray platforms, and that tissue sampling procedures differed between the three sub-studies included in our dataset. In dataset \#1 and \#2, basal plate biopsies were used for transcriptional analyses, whereas in dataset \#3, decidual tissue was collected by vacuum suction of the entire placental bed. These differences may pose a potential bias, as gene expression has been shown to differ depending on tissue sampling site [@pone.0069848-Sood1]. Inter- and intra-platform reproducibility has been shown to be good in terms of detecting differentially expressed genes [@pone.0069848-Barnes1]--[@pone.0069848-Zhang1]. However, the reproducibility of absolute transcription levels is poor, and pre-processing is required before comparisons of transcription values across platforms can be made. To deal with these limitations, and be able to make both inter- and intra-platform comparisons of transcription values, we performed inverse normal transformation. After this transformation, the distribution of transcription values is assumed equal for all probes, independent of study, sampling method and platform. However, PE-status, gestational age and tissue sampling method differed between studies, and consequently we had to include this as a factor giving a separate level for each study in the linear regression model. In our analyses, we exclusively searched for observations that agreed between datasets, and the limitations mentioned above will rather reduce the power of identifying differentially expressed genes than introduce false positive results. Combined with the fact that our pooled dataset only targets 14,678 genes, and that we are using a very stringent threshold for significance, our results likely represent only a small fraction of the total number of transcripts that are influenced by either PE or gestational age. Had all samples been collected by the same method and analysed on the same arrays, it is likely that a much larger number of differentially expressed transcripts would be identified. In our analyses, we did not allow for interaction between the study/tissue source and the effect of PE or gestational age on transcription values. The main reason for this is that the cause of such interaction would be impossible to determine (e.g. sampling method, microarray type, PE heterogeneity etc.). Instead, we focused on identifying shared effects across studies.

Another limitation in our dataset is the heterogeneity of the PE group. In dataset \#2, all cases had severe PE of which 5 were complicated by FGR. In dataset \#3 30 of 37 cases had severe PE or PE complicated by SGA, seven had mild PE. We recognise that this may indicate that some of our PE-associated transcripts may be linked to SGA pathogenesis or restricted to severe PE, and that it would have been preferable to use a more homogenous case group. The sample size of PE cases was too small to allow for any stratification in the analyses. It is therefore important to consider that our results might not be generalisable to all kinds of PE. However, PE is a complex disorder. Classifying individuals into e.g. severe and mild PE does not necessarily mean that these are different disorders. Rather, the diagnosis of both mild and severe PE are combinations of different quantitative characteristics, and at some pre-defined cut-off, the disorder is regarded as severe. This means that the underlying causes of PE might be as complex within the patients with severe PE as between cases with severe and mild PE. The NP group is also heterogeneous, including samples from preterm labour without infection (1/3 of these due to cervical insufficiency), elective terminations (of which the future pregnancy outcome is unknown), as well as normal pregnant women. Including cases with preterm labour may have influenced our results, as this condition with or without infection is likely to result from some sort of pathology that could result in gene expression changes. A possible shared pathology between preterm birth or PE might also result in similar changes in gene expression, which would reduce our power to identify PE-specific differentially expressed genes. However, it is almost impossible to match severe PE cases with regards to gestational age by using completely healthy individuals, as normal pregnancies in this gestational age range (week 24--36) are rare. The inclusion of samples with gestational age \<20 weeks may also have confounded our results, as the future pregnancy outcome is unknown, and they may have developed PE later in pregnancy. However, excluding these samples from the analyses did not change the results, but rather decreased the power due to the smaller sample size.

Unfortunately, we were not able validate the microarray results, e.g. through quantitative real-time (qRT-) PCR, for all our significant findings, mainly due to lack of RNA. However, validations have previously been performed for a subset of our genes: *ANGPTL2, CRH, TCF7L2, PLA2G7 and TCF7L2* [@pone.0069848-Loset1], [@pone.0069848-Winn2] with good results. Even though more comprehensive corroborative studies might have be useful for verifying the results, there are many examples where this is not feasible, e.g. due to lack of RNA [@pone.0069848-Rockett1]. It is also worth considering that microarray data are generally much more accurate compared to qRT-PCR. For qRT-PCR, housekeeping genes are assumed to be equally expressed in all samples, and commonly used for normalisation procedures. However, it has been shown that the expression of housekeeping genes vary dramatically between individuals and that the heritability is as high as 0.56 for some housekeeping genes [@pone.0069848-Goring1]. Consequently, housekeeping genes are not ideal for internal standardisation. The normalisation procedure performed for microarray experiments, based on the average expression level per individual, is likely to generate more precise estimates.

To our knowledge, this is the first study to simultaneously assess the effects of gestational age and PE-status on gene expression at the maternal-fetal interface. We found that a much large number of transcripts were influenced by gestational age compared to PE status. Based on this, we strongly recommend that adjustments for gestational age should be performed in similar studies. The large sample size achieved by pooling different datasets allowed us to apply a stringent threshold for significance, which has not been feasible in most previous studies. The transcripts identified in this study are likely to be influenced by gestational age or disease status, or even play a direct role in the development of PE.
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**Variation in transcription values depending on gestational age for all transcripts that were significantly associated with preeclampsia (PE).** Normalised transcription values are plotted for different gestational ages (weeks). The red points represent PE pregnancies and blue points normal pregnancies (NP). The lines are the estimated regression lines for gestational age (red line for PE and blue line for NP), separated by the regression coefficient for PE-status.
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